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We report 9 ciproﬂ  oxacin-resistant Salmonella enterica 
serotype Typhi isolates submitted to the US National 
Antimicrobial Resistance Monitoring System during 
1999–2008. The ﬁ   rst 2 had indistinguishable pulsed-ﬁ  eld 
gel electrophoresis patterns and identical gyrA and parC 
mutations. Eight of the 9 patients had traveled to India 
within 30 days before illness onset.
T
yphoid fever, caused by Salmonella enterica serotype 
Typhi, is a systemic bacterial illness that has been 
rare in the United States in the era of modern sanitation 
(1,2). However, typhoid fever remains common in many 
developing countries. In the United States, 72%–81% of 
patients with typhoid fever report international travel in the 
month before illness onset (1,3–5). Highest risk has been 
associated with travel to southern Asia (1–5).
Fluoroquinolones (e.g., ciproﬂ  oxacin) are frequently 
used to treat typhoid fever in adults (4,6). Ciproﬂ  oxacin 
resistance is rare; however, resistance to the quinolone 
nalidixic acid in the US National Antimicrobial Resistance 
Monitoring System (NARMS) increased from 19% of 
isolates tested in 1999 to 59% in 2008 (7). Nalidixic 
acid resistance in S. enterica serotype Typhi, which 
has been associated with overseas travel, particularly to 
southern Asia, correlates with decreased susceptibility to 
ciproﬂ  oxacin (MIC >0.12 μg/mL) (4–6,8). Increased risk 
for ﬂ  uoroquinolone treatment failure has been demonstrated 
in  Salmonella infections from strains with decreased 
susceptibility to ciproﬂ  oxacin (6,8,9). Chromosomal point 
mutations in the gyrA and parC topoisomerase genes 
are mechanisms of quinolone resistance in Salmonella 
spp. Other resistance mechanisms include efﬂ  ux pumps, 
reduced outer membrane permeability, and plasmid-borne 
genes (e.g., qnr, aac-6′-Ib-cr genes) (6,8,10–12). We report 
9 ciproﬂ   oxacin-resistant (MIC >4 μg/mL)  S. enterica 
serotype Typhi isolates detected in the United States during 
1999–2008.
The Cases
State public health laboratories receive Salmonella 
isolates from clinical diagnostic laboratories as part of routine 
surveillance. State and local health department ofﬁ  cials 
report demographic, clinical, and travel information about 
laboratory-conﬁ   rmed typhoid fever on a standard form 
to the Centers for Disease Control and Prevention (CDC, 
Atlanta, GA, USA). Participating states began submitting 
all  S. enterica serotype Typhi isolates to NARMS in 
1999; since 2003, all state public health laboratories have 
participated. Isolates were tested for susceptibility by using 
broth microdilution (Sensititre: Trek Diagnostics, Westlake, 
OH, USA). MICs were determined for 15 antimicrobial 
agents and interpreted by using Clinical and Laboratory 
Standards Institute (CLSI) criteria when available (Table 
1) (7,13). For ciproﬂ  oxacin-resistant isolates, subtyping by 
pulsed-ﬁ  eld gel electrophoresis (PFGE) was performed by 
using the protocol established by the National Molecular 
Subtyping Network for Foodborne Disease Surveillance 
(PulseNet) (14). PFGE pattern similarity was assessed by 
cluster analysis (Dice, UPGMA [unweighted pair group 
method using arithmetic averages]) and band-matching 
applications of BioNumerics software (Applied Maths, 
Sint-Martens-Latem, Belgium) and conﬁ   rmed by visual 
comparison (Figure). For ciproﬂ  oxacin-resistant  isolates 
detected for 1999–2005, sequencing of the quinolone 
resistance–determining region (QRDR; deﬁ  ned as amino 
acids 67–106 for gyrA) was performed according to the 
methods described by Crump et al. (6), and additional 
patient information (e.g., antimicrobial drug treatment) was 
requested by using a questionnaire with institutional review 
board approval.
During 1999–2005, we detected 2 (0.1%) cases of 
ciproﬂ  oxacin resistance among 1,690 S. enterica serotype 
Typhi isolates. Case reports follow.
In 2003, a 1-year-old girl had onset of fever 1 day 
before arriving in the United States from India. A blood 
specimen collected 3 days after fever onset yielded S. 
enterica serotype Typhi. Diarrhea or vomiting at time of 
specimen collection was not reported. Information about 
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was hospitalized for 14 days.
In 2005, a 2-year-old girl had onset of diarrhea, 
which was treated with oﬂ   oxacin, 2 days before she 
arrived in the United States from India. Seven days later, 
she continued to have diarrhea, and fever, vomiting, and 
abdominal cramps developed. She was hospitalized and 
treated with antimicrobial agents, including ciproﬂ  oxacin. 
Blood and fecal specimens collected 3 weeks after illness 
onset yielded S. enterica serotype Typhi. The patient was 
discharged after 14 days of hospitalization. She had lived 
in India for 6 months before traveling to the United States.
The S. enterica serotype Typhi isolates were resistant 
to ciproﬂ  oxacin (Tables 1, 2) and had indistinguishable 
PFGE patterns when restriction enzymes XbaI and 
BlnI were used: PulseNet-designated XbaI pattern 
JPPX01.0026 and BlnI pattern JPPA26.0110 (Table 
2; Figure). QRDR sequencing showed gyrA mutations 
resulting in a serine to tyrosine substitution at codon 83 
and an aspartic acid to asparagine substitution at codon 
87, and a parC mutation conferring a serine to isoleucine 
substitution at codon 80.
Seven (0.6%) ciproﬂ  oxacin-resistant infections were 
detected among patients from whom 1,131 S. enterica 
serotype Typhi isolates were submitted during 2006–2008 
(Table 2). The 7 cases occurred in 2006 and 2007. Patients 
were a median of 22 years of age (range 5–48 years); 5 
(71%) were male. All 6 patients with known travel histories 
reported travel to India in the 30 days before illness onset. 
In addition to XbaI JPPX01.0026 and BlnI JPPA26.0110, 3 
different XbaI and BlnI pattern combinations were detected 
in the 7 isolates (Table 2; Figure).
Conclusions
We describe ciproﬂ  oxacin-resistant  S. enterica 
serotype Typhi isolates from 9 patients in the United 
States. The ﬁ   rst 5 cases were reported previously in 
aggregated form, without molecular characterization 
of the isolates (5). The ﬁ   rst 2 patients were young 
children apparently infected in India in 2003 and 2005. 
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Table 1. MICs of antimicrobial agents tested for 9 ciprofloxacin-resistant Salmonella enterica serotype Typhi isolates detected in the 
National Antimicrobial Resistance Monitoring System, United States, 1999–2008 
Antimicrobial class and agent* 
MIC, μg/mL,* by patient no. (isolate) 
Patient 1 
(MA-03) 
Patient 2† 
(CA-05) 
Patient 3 
(CA-06) 
Patient 4 
(TX-06) 
Patient 5 
(AZ-06) 
Patient 6 
(NY-07) 
Patient 7 
(CA-07) 
Patient 8 
(NJ-07) 
Patient 9 
(LAC-07)
Quinolones 
 Ciprofloxacin  >4 >4 >4 >4 >4 >4 >4 >4 >4
 Nalidixic  acid  >32 >32 >32 >32 >32 >32 >32 >32 >32
Aminoglycosides 
 Amikacin  <0 . 5 1 1111111
 Gentamicin  <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25
 Kanamycin  <8< 8< 8< 8< 8< 8< 8< 8< 8
 Streptomycin  <32 <32 <32 >64 <32 <32 <32 <32 <32
ȕ-lactam–ȕ-lactamase inhibitor 
 Amoxicillin-clavulanic  acid  <1/0.5 <1/0.5 <1/0.5 8/4 <1/0.5 <1/0.5 <1/0.5 <1/0.5 <1/0.5
Cephems 
 Cefoxitin  4 4 4 4 2 4 4 4 4
 Ceftiofur  0.5 0.5 0.5 0.5 0.25 0.5 0.5 0.5 0.5
 Ceftriaxone  <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25
Folate pathway inhibitors 
 Sulfonamide‡  >512 >256 <16 >256 >256 <16 >256 <16 <16
 Trimethoprim- 
 sulfamethoxazole 
>4/76 >4/76 <0.12/
2.38
>4/76 >4/76 <0.12/
2.38
>4/76 <0.12/
2.38
<0.12/
2.38
Penicillins   
 Ampicillin  2 <1< 1> 3 2< 1< 1< 1< 1< 1
Phenicols
 Chloramphenicol  4 4 4 >32 4 4 4 4 4
Tetracyclines    
 Tetracycline  >32 >32 <4< 4> 3 2< 4> 3 2< 4< 4
*Classes of antimicrobial agents defined by the Clinical and Laboratory Standards Institute (CLSI) were used to categorize agents (7,13). MICs were 
interpreted by using CLSI criteria when available (7,13): ciprofloxacin (resistance breakpoint, >4 μg/mL); nalidixic acid (>32); amikacin (>64); gentamicin 
(>16); kanamycin (>64); amoxicillin-clavulanic acid (>32/16); cefoxitin (>32); ceftiofur (>8); ceftriaxone (>4); sulfamethoxazole/sulfisoxazole (>512); 
trimethoprim-sulfamethoxazole (>4/76); ampicillin (>32); chloramphenicol (>32); and tetracycline (>16). For streptomycin, resistance was defined as MIC 
>64 μg/mL (7). If growth was not inhibited by the highest concentration of the agent in the panel, the MIC was reported as above the highest
concentration. 
†Isolate was cultured from a blood specimen. Another isolate was cultured from fecal samples, which had MIC <0.5 μg/mL for amikacin and same MICs 
for other agents tested. 
‡Sulfamethoxazole was used during 1999–2003 and sulfisoxazole since 2004 to represent sulfonamides. Ciproﬂ  oxacin-Resistant S. enterica ser. Typhi
Six additional patients, who were detected in 2006 and 
2007, also reported travel to India. Travel to the Indian 
subcontinent has been associated with nalidixic acid–
resistant S. enterica serotype Typhi infection; however, 
ciproﬂ  oxacin-resistant infections are rarely reported by 
using current CLSI criteria (4,5,11). Other resistance 
patterns were ﬁ  rst described in southern Asia, where the 
incidence of typhoid fever is high and antimicrobial agents 
are widely available without prescription, providing the 
opportunity for the development and selection of resistant 
strains (8).
Other than reports by 8 patients of travel to India, 
we have no information about possible shared exposures, 
such as speciﬁ  c locations visited, sources of food or water, 
or contact with carriers of S. enterica serotype Typhi. 
However, the indistinguishable PFGE XbaI and BlnI 
patterns and identical gyrA and parC mutations of isolates 
from the ﬁ   rst 2 patients suggest that, although typhoid 
fever occurred nearly 2 years apart, the same ciproﬂ  oxacin-
resistant strain is likely to have been involved. After 2005, 
different XbaI and BlnI patterns have been identiﬁ  ed in 
ciproﬂ   oxacin-resistant isolates, indicating independent 
selection of ciproﬂ  oxacin resistance in different strains.
The gyrA and parC mutations of isolates from the ﬁ  rst 2 
patients were reported in ciproﬂ  oxacin-resistant S. enterica 
serotype Typhi in India (11). The 2 gyrA mutations are well 
characterized and known to be associated with quinolone 
resistance; 2 point mutations in gyrA and 1 in parC confer 
ﬂ   uoroquinolone resistance (8,10–12). Further studies, 
including characterization of other resistance mechanisms, 
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Figure. Pulsed-ﬁ  eld gel electrophoresis (PFGE) XbaI (A) and BlnI (B) patterns of 9 ciproﬂ  oxacin-resistant Salmonella enterica serotype 
Typhi isolates detected in the National Antimicrobial Resistance Monitoring System, 1999–2008. PFGE pattern similarity was assessed by 
cluster analysis (Dice, UPGMA [unweighted pair group method using arithmetic average]) and band-matching applications of BioNumerics 
software (Applied Maths, Sint-Martens-Latem, Belgium) and conﬁ  rmed by visual comparison. PulseNet only considers band markings 
found within the scale of the global standard, which are all bands between 20.5 kb and 1,135 kb. The cluster parameters are Dice 
coefﬁ  cient and UPGMA with the tolerance of band position of 1.5% and optimization of 1.5%.
Table 2. Patient and isolate description, resistance to other antimicrobial agents, PFGE pattern, and travel reported for 9 ciprofloxacin-
resistant Salmonella enterica serotype Typhi infections detected in the National Antimicrobial Resistance Monitoring System, United 
States, 1999–2008* 
Patient no. 
(isolate) 
Age, y/ 
sex Site
Specimen
collection year 
Specimen
source
Resistance to 
other agents 
PFGE XbaI
pattern† 
PFGE BlnI
pattern‡ Travel§ 
1 (MA-03)  1/F MA 2003  Blood Cot, Fis, Nal, Tet  JPPX01.0026 JPPA26.0110 India
2 (CA-05)  2/F CA 2005  Blood Cot, Fis, Nal, Tet  JPPX01.0026 JPPA26.0110 India
3 (CA-06)  26/F CA 2006  Blood Nal JPPX01.0506 JPPA26.0187 India
4 (TX-06)  8/M TX 2006  Blood Amp, Chl, Cot, 
Fis, Nal, Str 
JPPX01.0465 JPPA26.0170 India,
other 
5 (AZ-06)  5/M AZ 2006  Stool Cot, Fis, Nal, Tet  JPPX01.0026 JPPA26.0110 India
6 (NY-07)  6/M NYC  2007  Stool Nal JPPX01.0506 JPPA26.0187 India
7 (CA-07)  22/M CA 2007  Stool Cot, Fis, Nal, Tet  JPPX01.0026 JPPA26.0110 India
8 (NJ-07)  28/M NJ 2007  Blood Nal JPPX01.0026 JPPA26.0002 India
9 (LAC-07)  48/F LAC 2007  Blood Nal JPPX01.0506 JPPA26.0187 Unknown 
*PFGE, pulsed-field gel electrophoresis. State/local public health laboratories that submitted isolates: MA, Massachusetts; CA, California; TX, Texas; AZ, 
Arizona; NYC, New York City; NJ, New Jersey; LAC, Los Angeles County, California. Resistance to antimicrobial agents other than ciprofloxacin: Cot, 
trimethoprim–sulfamethoxazole; Fis, sulfamethoxazole or sulfisoxazole; Nal, nalidixic acid; Tet, tetracycline; Amp, ampicillin; Chl, chloramphenicol; Str, 
streptomycin. 
†National Molecular Subtyping Network for Foodborne Disease Surveillance (PulseNet)–designated PFGE patterns using restriction enzyme XbaI (data 
as of 2009 Oct 21): JPPX01.0026, the most common XbaI pattern among 3,233 isolates with reported XbaI pattern in PulseNet, was detected in 486 
(15.0%); JPPX01.0465 and JPPX01.0506 each were detected in 12 (0.4%) isolates.  
‡PulseNet-designated PFGE patterns using restriction enzyme BlnI (data as of 2009 Oct 21): JPPA26.0002, the most common BlnI pattern among 409 
isolates with reported BlnI pattern in PulseNet, was detected in 61 (14.9%) isolates; JPPA26.0110 was detected in 5 (1.2%), JPPA26.0187 was detected 
in 3 (0.7%), and JPPA26.0170 was detected in 1 (0.2%). 
§Travel outside the United States reported in the 30 d before illness onset; patient 4 also traveled to Bangladesh and the United Arab Emirates. are needed to track the evolution of ﬂ  uoroquinolone-
resistant S. enterica serotype Typhi.
Although the ciproﬂ   oxacin resistance we detected 
using current CLSI criteria is rare in S. enterica serotype 
Typhi, nalidixic acid resistance, which correlates with 
decreased susceptibility to ciproﬂ  oxacin, has increased (7). 
Clinicians should be aware that infection with Salmonella 
spp. with decreased susceptibility to ciproﬂ  oxacin  may 
not respond satisfactorily to this agent (6,8,9,13,15). In 
addition, identiﬁ  cation of ciproﬂ  oxacin-resistant cases has 
been increasing. In the presence of quinolone resistance, 
third-generation cephalosporins, such as ceftriaxone, 
can be used (2,6,8,15). Recent clinical trials suggest that 
azithromycin might be useful for treating uncomplicated 
typhoid fever (2,8,9,15). Recommendations for empiric 
treatment of typhoid fever in the United States are best 
developed by using information about antimicrobial drug 
resistance trends in isolates from countries where the 
infection was acquired.
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